Project Grant RF1AG082704
Award Date 9/1/23
Completion Date 8/31/26
Dollars Obligated $2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, Stati Uniti
Similar Awards
- The National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), awarded a $1,684,689 project grant to Weill Medical College of Cornell University to study the role of microglial lysosomes in the degradation of amyloid-beta, a key pathological feature of Alzheimer's disease. The 3-year project aims to characterize the process of "digestive exophagy" used by microglia to limit the expansion of amyloid-beta plaques, as well as explore the effects of genetic...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $433,125 will fund a study to investigate the relationship between microglia, neurons, and tau pathology in Alzheimer's disease. The research will utilize a novel model system of microglial co-cultures with hippocampal assembloids derived from patient-derived induced pluripotent stem cell (iPSC) lines with MAPT mutations and healthy controls. The goal is to explore how bidirectional changes...
- This $427,625 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to elucidate the mechanisms by which microgliopathy, a genetic neurological disorder, causes early-onset dementia. The research will investigate how the loss of the DAP12 protein in microglia, the immune cells of the brain, leads to heightened signaling of the RUNX and STAT3 pathways. This dysregulation is hypothesized to disrupt normal microglial functions and induce brain pathology and...
- Project Grant Award Summary The National Institute on Aging (NIA) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $839,933 under the Aging Research program (CFDA 93.866) to investigate the role of N6-methyladenosine (M6A) RNA modifications in microglial dysfunction and Alzheimer's disease pathogenesis. The five-year project, commencing September 1, 2025 and concluding May 31, 2030, will deliver research services focused on systematically mapping M6A RNA modification...
- This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $10,847,672 to the J. David Gladstone Institutes, a non-profit biomedical research organization, to investigate the vascular-immune mechanisms underlying cerebral amyloid angiopathy (CAA) and Alzheimer's disease pathology. The research aims to elucidate the key microglial mechanisms regulating the formation of vascular CAA versus parenchymal amyloid-beta plaques, define single-cell and...
- This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $509,413 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 15, 2025, with completion targeted for May 31, 2030. The award funds research investigating epitranscriptomic regulation of microglia in Alzheimer's Disease (AD), specifically examining how adenosine methylation (m6A) modifications control microglial cell...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Massachusetts General Hospital $975,148 on May 15, 2025, under the Aging Research program (CFDA 93.866) to investigate the role of reactive astrocytes in tau protein propagation and clearance in Alzheimer's disease. The research project, which extends through February 28, 2030, will generate scientific knowledge regarding the mechanisms by which glial fibrillary acidic protein (GFAP) upregulation in astrocytes may...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Advantage Therapeutics, Inc. a Project Grant of $1,249,957 (awarded September 20, 2025) under the Aging Research program (CFDA 93.866) to conduct preclinical and Investigational New Drug (IND)-enabling studies on a novel small-molecule disease-modifying therapeutic for Alzheimer's disease. The proposed treatment is designed to reduce brain inflammation and restore phagocytosis, thereby improving amyloid...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $9.78 million to the Institute For Molecular Medicine Inc. on August 1, 2025, under the Aging Research program (CFDA 93.866) to conduct a multicenter Phase 1 clinical trial evaluating the safety and immunogenicity of AV-1980R/A, a preventive tau vaccine, in cognitively unimpaired preclinical Alzheimer's disease (AD) participants. The five-year project (through July 31, 2030) represents a strategic shift in AD...